Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 11/20 | 1.00 |
| ▸ | TUBB4A | P04350 | 7/20 | 1.00 |
| ▸ | TUBB | P07437 | 7/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 7/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 7/20 | 1.00 |
| ▸ | TUBB4B | P68371 | 7/20 | 1.00 |
| ▸ | TUBB3 | Q13509 | 7/20 | 1.00 |
| ▸ | TUBB2A | Q13885 | 7/20 | 1.00 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 1.00 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 1.00 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.59 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.57 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.57 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30063036 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4967209 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL1764919 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL30466670 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29815038 | 1.00 | TUBB1 (1.00) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7499124 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL7496691 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671618 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL23671617 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29815036 | 0.90 | TUBB1 (0.81) | TUBB1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116332802-B | Tubulin and NRP1 double-target compound and preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-116332802-A | Tubulin and NRP1 double-target compound and preparation method and application thereof | 中国药科大学 | 2023-06-27 | — | — | CN | disclosed |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) | 2022-03-22 | — | — | US | disclosed |
| US-20210230122-A1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF | SHANGHAI ECUST BIOMEDICINE CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| EP-2562154-A1 | Method for preparing combretastatin | SANOFI (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2562154-A1 | Method for preparing combretastatin | SANOFI (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-2354118-A1 | Process for the preparation of combretastatine | Aventis Pharma S.A. (FR) | 2011-08-10 | — | — | EP | disclosed |
| EP-2348012-A1 | PROCESS FOR THE PREPARATION OF COMBRETASTATINE | Aventis Pharma S.A. (FR) | 2011-07-27 | — | — | EP | disclosed |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2011-05-26 | — | — | US | disclosed |
| EP-2252572-A1 | METHOD FOR PREPARING COMBRETASTATIN | Sanofi-Aventis (FR) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009118474-A1 | METHOD FOR PREPARING COMBRETASTATIN | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | WO | disclosed |
| US-6759555-B2 | CONDENSING (3,4,5-TRIMETHOXYBENZYL)TRIPHENYLPHOSPHONIUM BROMIDE WITH 3-NITRO-4-METHOXYBENZALDEHYDE, REDUCING THE NITRO INTERMEDIATE TO FORM 2-METHOXY-5-(2-(3,4,5-TRIMETHOXYPHENYL)-ETHENYL)ANILINE | AVENTIS PHARMA S.A. (FR) | 2004-07-06 | — | — | US | disclosed |
| US-20030220404-A1 | Process for the preparation of combretastatins | AVENTIS PHARMA S.A. (FR) | 2003-11-27 | — | — | US | disclosed |
| US-6350777-B2 | METHOXY/ETHOXY SUBSTITUTED 3-AROYL-2-ARYLBENZO(B)THIOPHENES AND BENZO(B)THIOPHENE ANALOGUES; ANTITUMOR AGENTS; CYTOTOXICITY | BAYLOR UNIVERSITY | 2002-02-26 | — | — | US | disclosed |
| EP-0984954-A4 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | UNIV BAYLOR (US) | 2002-01-16 | — | — | EP | disclosed |
| US-20010034454-A1 | Description anti-mitotic agents which inhibit tubulin polymerization | BYLOR UNIVERSITY AND ARIZONA DESEASE CONTROL RESEARCH COMMISSION | 2001-10-25 | — | — | US | disclosed |
| US-6162930-A | Anti-mitotic agents which inhibit tubulin polymerization | BAYLOR UNIVERSITY (US) | 2000-12-19 | — | — | US | disclosed |
| EP-0984954-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998039323-A1 | ANTI-MITOTIC AGENTS WHICH INHIBIT TUBULIN POLYMERIZATION | BAYLOR UNIVERSITY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034454-A1 | Description anti-mitotic agents which inhibit tubulin polymerization | TUBB, TUBB1, TUBB3 | TUBB1 2/4885TUBB4A 4/4885TUBB 1/4885 |
| US-20030220404-A1 | Process for the preparation of combretastatins | TGFB2, HMGCR, TGFB1 | TUBB1 577/4885TUBB4A 1286/4885TUBB 709/4885 |
| US-20110124899-A1 | METHOD FOR PREPARING COMBRETASTATIN | PCSK9, PCSK7, HMGCR | TUBB1 1796/4885TUBB4A 1410/4885TUBB 1639/4885 |
| US-11279678-B2 | 5-fluorouracil derivatives, preparation methods and uses thereof | VEGFA, FLT4, FAU | TUBB1 310/4885TUBB4A 208/4885TUBB 242/4885 |
| US-20210230122-A1 | 5-FLUOROURACIL DERIVATIVES, PREPARATION METHODS AND USES THEREOF | VEGFA, FLT4, FAU | TUBB1 310/4885TUBB4A 208/4885TUBB 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.